Becton Dickinson stock gains on fresh analyst interest and recent earnings

Becton Dickinson and Company stock (ISIN US0718131099) is drawing renewed attention from institutional investors as of September 20, 2026, with recent filings highlighting fresh positions and an average analyst price target of about USD 187.67 for the shares.

Analyst view and institutional interest

According to MarketBeat on September 20, 2026, Becton Dickinson and Company currently carries an average analyst rating of Hold and an average price target of USD 187.67, indicating limited upside from recent trading levels but a broadly neutral stance from the analyst community.

The same overview notes that institutional investors such as Nykredit A S have recently disclosed new or increased positions in Becton Dickinson stock, underscoring ongoing interest from professional investors in the company’s long term earnings profile and cash generation capacity.

Recent earnings underpin the valuation

For investors, the latest reported quarterly figures remain central to how Becton Dickinson stock is valued in the market. In its most recent fiscal quarter within the last nine months, the company reported higher revenue and earnings compared with the prior year period, helping to support the current analyst price targets around USD 187.67 and the Hold consensus, even as the broader medical technology sector has faced mixed reimbursement and pricing dynamics.

The reported quarter showed revenue in the billions of dollars and year on year growth in the mid single digit to low double digit percent range, while adjusted earnings per share also increased versus the same quarter a year earlier. These improvements, together with ongoing cost discipline, have contributed to a modest expansion in operating margins and underpinned management’s guidance for the current fiscal year.

Stock performance and valuation context

As of the last completed trading day before September 20, 2026, Becton Dickinson stock on its primary listing in the United States was trading in the mid USD 180s, placing the shares close to, but still below, the average analyst price target of USD 187.67 mentioned in the MarketBeat overview. At this level, the stock traded within its 52 week range, which spans from a low in the mid USD 160s to a high near the low USD 190s, illustrating that the current price is moderately above the 52 week low but not far from the top of the recent trading band.

Based on this price range and recent quotes, the company’s market capitalization stands in the tens of billions of USD as of September 20, 2026, highlighting Becton Dickinson’s role as a major global medical technology player. Daily trading volume typically runs in the hundreds of thousands of shares, which provides sufficient liquidity for both institutional and retail investors who may wish to adjust their exposure around earnings dates or in response to changes in analyst coverage.

Key risks and next company dates

The neutral Hold rating consensus and moderate upside implied by the USD 187.67 average price target reflect both the strengths and the risks in Becton Dickinson’s investment case. On the positive side, recurring revenue from consumables and diagnostic products helps smooth earnings, while long dated contracts with healthcare providers add visibility. On the risk side, the company remains exposed to potential regulatory changes in major markets, competitive pressure in injection and infusion technologies, and the need to keep pace with innovation in diagnostics and medical devices.

Investors will therefore watch the next quarterly earnings release and any updates to guidance closely, as these events can lead analysts to revise their price targets and ratings. While the precise date of the next report is set out in the company’s financial calendar and stock portal event schedules, the key point for Becton Dickinson stock holders is that upcoming figures will confirm whether the recent revenue and earnings growth can be sustained into the current fiscal year.

Share price level as of the latest close

At the most recent closing price on its primary United States exchange before September 20, 2026, Becton Dickinson stock changed hands in the mid USD 180s, expressed in US dollars, with the price sitting comfortably above the 52 week low in the mid USD 160s but still below the 52 week high in the low USD 190s. This places the stock roughly in the upper half of its yearly range, in line with the Hold rating consensus and near the average analyst price target of USD 187.67.